Pharmaceuticals

Kedrab Market Forecast 2026–2035: How to Leverage Market Growth

March 5, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the kedrab market from 2026–2035 with trusted insights from The Business Research Company

What is the expected shift in the Kedrab Market’s size between 2026 and 2030?

The growth experienced historically was a result of elevated rabies mortality rates, a reliance on immunoglobulin treatments, restricted early access to vaccines, implemented public health emergency protocols, and the management of rabies predominantly within hospitals.

Anticipated growth over the forecast period is primarily driven by an uptick in animal bite occurrences, the proliferation of rabies awareness initiatives, an increase in emergency care infrastructure, enhanced accessibility to monoclonal antibodies, and heightened government expenditure on rabies prevention. Significant trends during this period are expected to include the expanding adoption of rabies passive immunization, the enlargement of post-exposure prophylaxis programs, an intensified focus on controlling zoonotic diseases, a growing need for emergency immunotherapy, and the fortification of public health response systems.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20124&type=smp

Which Drivers Are Shaping Strategic Decisions In The Kedrab Market?

The rising occurrence of rabies is anticipated to boost the kedrab market moving forward. Rabies is an almost always fatal condition caused by contact with rabid animals, posing a critical public health concern, especially in regions with limited access to vaccines. The increasing incidence of rabies is influenced by inadequate vaccination of domestic animals, restricted access to post-exposure prophylaxis, and the prevalence of rabies in wildlife, particularly in underserved regions. Kedrab is a human rabies immunoglobulin utilized for immediate passive immunity in individuals exposed to the rabies virus, offering crucial protection until active immunity develops through vaccination. For instance, in April 2024, according to the South Dakota Department of Health, a US-based government agency, in 2023, approximately 20 animals in South Dakota were confirmed to have rabies, indicating a 122% increase from the 9 cases reported in 2022. Therefore, the escalating incidence of rabies propels the kedrab market.

What Segment Classifications Make Up The Kedrab Market?

The kedrab market covered in this report is segmented –

1) By Indication: Post-Exposure Prophylaxis For Rabies, Treatment For Patients Exposed To Suspected Rabid Animals

2) By Formulation: Injectable Formulation, Lyophilized Powder For Reconstitution

3) By Route Of Administration: Intramuscular Injection, Subcutaneous Injection

4) By Distribution Channel: Direct Sales, Wholesalers And Distributors, Retail Pharmacies, Online Pharmacies

5) By End User: Hospitals, Emergency Departments, Specialty Clinics, Public Health Organizations

Which Trends Are Expected To Influence The Kedrab Market In The Upcoming Years?

Leading companies in the kedrab market are focusing on developing innovative solutions and securing regulatory mechanisms, such as exclusive licensing and distribution continuation notices, to expand their commercial reach and presence in the U.S. Such a notice is an official statement from a pharmaceutical or biotechnology company, confirming the extension or renewal of an existing agreement that grants exclusive rights to license, distribute, or commercialize a particular product. For example, in July 2023, Kamada Ltd., an Israel-based plasma-derived biopharmaceutical firm, announced that Kedrion Biopharma exercised its option to prolong the exclusive U.S. distribution agreement for KEDRAB, a human rabies immune globulin utilized for post-exposure prophylaxis. KEDRAB offers immediate passive immunity against rabies after potential exposure, with proven efficacy, safety, and regulatory approval in the U.S. This two-year extension ensures continuous availability and supply stability, supporting Kedrion’s commercial distribution infrastructure and its strategic position within the U.S. immunoglobulin market, thereby enhancing patient access and public health preparedness.

Which Leading Companies Dominate The Kedrab Market Share?

Major companies operating in the kedrab market are Kamada Ltd., Kedrion Biopharma Inc.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/kedrab-global-market-report

How Does The Kedrab Market Perform Across Major Global Regions?

North America was the largest region in the kedrab market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the kedrab market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Kedrab Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=20124&type=smp

Browse Through More Reports Similar to the Global Kedrab Market 2026, By The Business Research Company

Data Lake Market Report 2026

https://www.thebusinessresearchcompany.com/report/data-lake-global-market-report

Online Fashion Retail Market Report 2026

https://www.thebusinessresearchcompany.com/report/online-fashion-retail-global-market-report

Naphthalene Sulfonate Market Report 2026

https://www.thebusinessresearchcompany.com/report/naphthalene-sulfonate-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795